The common link is that GLP-1s activate receptors that then work on driving down metabolic risk factors through the following mechanisms: Enhancing glucose dependent insulin secretion Slowing gastric emptying and decreasing appetite Reducing postprandial glucagon and food intake UpToDate 2 : (1) ingestion of food results in (2) release of gastrointestinal peptides (GLP-1 and GIP: glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide) and (3) pancreatic beta cell hormones (insulin and amylin)
Retatrutide 10mg is frequently studied alongside Semaglutide and Tirzepatide to evaluate the incremental metabolic effects of adding GIP and glucagon receptor activation
Notably, 21 percent of adults in February 2026 were not sure whether GLP-1s are risky or not
ZOA gains +19pp, Bang gains +21pp, Reign gains +20pp, PRIME gains +17pp
Figure 1 Screening for kidney disease in individuals with diabetes
de Mesquita FC, Guixe-Muntet S, Fernandez-Iglesias A, Maeso-Diaz R, Vila S, Hide D, et al